

# Tom Decroo

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2971946/publications.pdf>

Version: 2024-02-01

111  
papers

2,207  
citations

236925

25  
h-index

254184

43  
g-index

115  
all docs

115  
docs citations

115  
times ranked

2934  
citing authors

#	ARTICLE	IF	CITATIONS
1	Distribution of Antiretroviral Treatment Through Self-Forming Groups of Patients in Tete Province, Mozambique. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2011, 56, e39-e44.	2.1	167
2	Social Consequences of Ebola Containment Measures in Liberia. <i>PLoS ONE</i> , 2015, 10, e0143036.	2.5	161
3	Community-based antiretroviral therapy programs can overcome barriers to retention of patients and decongest health services in sub-Saharan Africa: a systematic review. <i>International Health</i> , 2013, 5, 169-179.	2.0	136
4	Four-year retention and risk factors for attrition among members of community <scp>ART</scp> groups in <scp>T</scp>ete, <scp>M</scp>ozambique. <i>Tropical Medicine and International Health</i> , 2014, 19, 514-521.	2.3	98
5	Psychological Distress among Ebola Survivors Discharged from an Ebola Treatment Unit in Monrovia, Liberia – A Qualitative Study. <i>Frontiers in Public Health</i> , 2016, 4, 142.	2.7	94
6	The Contribution of Ebola Viral Load at Admission and Other Patient Characteristics to Mortality in a MÃ©decins Sans FrontiÃ©res Ebola Case Management Centre, Kailahun, Sierra Leone, June–October 2014. <i>Journal of Infectious Diseases</i> , 2015, 212, 1752-1758.	4.0	88
7	Management of pregnant women infected with Ebola virus in a treatment centre in Guinea, June 2014. <i>Eurosurveillance</i> , 2014, 19, .	7.0	76
8	Principles for constructing a tuberculosis treatment regimen: the role and definition of core and companion drugs. <i>International Journal of Tuberculosis and Lung Disease</i> , 2018, 22, 239-245.	1.2	65
9	A Qualitative Assessment of a Community Antiretroviral Therapy Group Model in Tete, Mozambique. <i>PLoS ONE</i> , 2014, 9, e91544.	2.5	59
10	Sustainability of a community-based anti-retroviral care delivery model – a qualitative research study in Tete, Mozambique. <i>Journal of the International AIDS Society</i> , 2014, 17, 18910.	3.0	51
11	How to bring residents’s psychosocial well-being to the heart of the fight against Covid-19 in Belgian nursing homes? A qualitative study. <i>PLoS ONE</i> , 2021, 16, e0249098.	2.5	49
12	Adapting a community-based ART delivery model to the patients’s needs: a mixed methods research in Tete, Mozambique. <i>BMC Public Health</i> , 2014, 14, 364.	2.9	48
13	Effect of Community ART Groups on retention-in-care among patients on ART in Tete Province, Mozambique: a cohort study. <i>BMJ Open</i> , 2017, 7, e016800.	1.9	45
14	Lessons learned during down referral of antiretroviral treatment in Tete, Mozambique. <i>Journal of the International AIDS Society</i> , 2009, 12, 6-6.	3.0	43
15	Dangerous crossing: demographic and clinical features of rescued sea migrants seen in 2014 at an outpatient clinic at Augusta Harbor, Italy. <i>Conflict and Health</i> , 2016, 10, 14.	2.7	41
16	Community ART Support Groups in Mozambique: The Potential of Patients as Partners in Care. <i>PLoS ONE</i> , 2016, 11, e0166444.	2.5	40
17	Delivery of an Ebola Virus-Positive Stillborn Infant in a Rural Community Health Center, Sierra Leone, 2015. <i>American Journal of Tropical Medicine and Hygiene</i> , 2016, 94, 417-419.	1.4	39
18	Are Expert Patients an Untapped Resource for ART Provision in Sub-Saharan Africa?. <i>AIDS Research and Treatment</i> , 2012, 2012, 1-8.	0.7	38

#	ARTICLE	IF	CITATIONS
19	Post-Traumatic Stress Reactions in Ebola Virus Disease Survivors in Sierra Leone. <i>Emergency Medicine: Open Access</i> , 2015, 05, .	0.1	38
20	Ebola Virus in Breast Milk in an Ebola Virusâ€“Positive Mother with Twin Babies, Guinea, 2015. <i>Emerging Infectious Diseases</i> , 2016, 22, 759-760.	4.3	36
21	Patients struggle to access effective health care due to ongoing violence, distance, costs and health service performance in Afghanistan. <i>International Health</i> , 2015, 7, 169-175.	2.0	35
22	Prevalence and drivers of false-positive rifampicin-resistant Xpert MTB/RIF results: a prospective observational study in Rwanda. <i>Lancet Microbe</i> , The, 2020, 1, e74-e83.	7.3	35
23	Lactating mothers infected with Ebola virus: EBOV RT-PCR of blood only may be insufficient. <i>Eurosurveillance</i> , 2015, 20, .	7.0	35
24	Short-Course Regimen for Multidrug-Resistant Tuberculosis: A Decade of Evidence. <i>Journal of Clinical Medicine</i> , 2020, 9, 55.	2.4	34
25	Pretomanid for tuberculosis: a systematic review. <i>Clinical Microbiology and Infection</i> , 2022, 28, 31-42.	6.0	30
26	Describing readmissions to an Ebola case management centre (CMC), Sierra Leone, 2014. <i>Eurosurveillance</i> , 2014, 19, 20924.	7.0	27
27	Journey towards universal viral load monitoring in Maputo, Mozambique: many gaps, but encouraging signs. <i>International Health</i> , 2017, 9, 206-214.	2.0	26
28	Management of multidrug-resistant tuberculosis with shorter treatment regimen in Niger: Nationwide programmatic achievements. <i>Respiratory Medicine</i> , 2020, 161, 105844.	2.9	26
29	Reduction of diagnostic and treatment delays reduces rifampicin-resistant tuberculosis mortality in Rwanda. <i>International Journal of Tuberculosis and Lung Disease</i> , 2020, 24, 329-339.	1.2	26
30	Acquired bedaquiline resistance during the treatment of drug-resistant tuberculosis: a systematic review. <i>JAC-Antimicrobial Resistance</i> , 2022, 4, dlac029.	2.1	24
31	Local constraints to access appropriate malaria treatment in the context of parasite resistance in Cambodia: a qualitative study. <i>Malaria Journal</i> , 2017, 16, 81.	2.3	23
32	Getting HIV Treatment to the Most People. <i>Science</i> , 2012, 337, 298-300.	12.6	22
33	Retention and predictors of attrition among patients who started antiretroviral therapy in Zimbabweâ€™s national antiretroviral therapy programme between 2012 and 2015. <i>PLoS ONE</i> , 2020, 15, e0222309.	2.5	21
34	Community-Based ART Resulted in Excellent Retention and Can Leverage Community Empowerment in Rural Lesotho, A Mixed Method Study. <i>HIV/AIDS Research and Treatment: Open Journal</i> , 2015, 2, 44-50.	0.2	21
35	World Health Organization 2018 treatment guidelines for rifampicin-resistant tuberculosis: uncertainty, potential risks and the way forward. <i>International Journal of Antimicrobial Agents</i> , 2020, 55, 105822.	2.5	19
36	Characteristics and early clinical outcomes of key populations attending comprehensive community-based HIV care: Experiences from Nasarawa State, Nigeria. <i>PLoS ONE</i> , 2018, 13, e0209477.	2.5	17

#	ARTICLE	IF	CITATIONS
37	ARTadherence clubs in the Western Cape of South Africa: what does the sustainability framework tell us? A scoping literature review. Journal of the International AIDS Society, 2019, 22, e25235.	3.0	17
38	The perceived impact of isoniazid resistance on outcome of first-line rifampicin-throughout regimens is largely due to missed rifampicin resistance. PLoS ONE, 2020, 15, e0233500.	2.5	16
39	Assessment of the MSF triage system, separating patients into different wards pending Ebola virus laboratory confirmation, Kailahun, Sierra Leone, July to September 2014. Eurosurveillance, 2015, 20, .	7.0	16
40	Viral load detection and management on first line ART in rural Rwanda. BMC Infectious Diseases, 2019, 19, 8.	2.9	15
41	Lessons learnt from TB screening in closed immigration centres in Italy. International Health, 2016, 8, 324-329.	2.0	13
42	Predictors of virological failure among people living with HIV receiving first line antiretroviral treatment in Myanmar: retrospective cohort analysis. AIDS Research and Therapy, 2021, 18, 16.	1.7	13
43	Patient-mix, programmatic characteristics, retention and predictors of attrition among patients starting antiretroviral therapy (ART) before and after the implementation of HIV "Treat All" in Zimbabwe. PLoS ONE, 2020, 15, e0240865.	2.5	13
44	Favipiravir "a prophylactic treatment for Ebola contacts?. Lancet, The, 2015, 385, 2350.	13.7	12
45	Initial resistance to companion drugs should not be considered an exclusion criterion for the shorter multidrug-resistant tuberculosis treatment regimen. International Journal of Infectious Diseases, 2020, 100, 357-365.	3.3	12
46	High rifampicin-resistant TB cure rates and prevention of severe ototoxicity after replacing the injectable by linezolid in early stage of hearing loss. European Respiratory Journal, 2021, 57, 2002250.	6.7	12
47	What was the effect of the West African Ebola outbreak on health programme performance, and did programmes recover?. Public Health Action, 2017, 7, 1-2.	1.2	11
48	First-line tuberculosis treatment with double-dose rifampicin is well tolerated. International Journal of Tuberculosis and Lung Disease, 2020, 24, 499-505.	1.2	11
49	Second-line injectable drugs for rifampicin-resistant tuberculosis: better the devil we know?. Journal of Antimicrobial Chemotherapy, 2021, 76, 831-835.	3.0	9
50	<i>Mycobacterium tuberculosis</i> borderline <i>rpoB</i> mutations: emerging from the unknown. European Respiratory Journal, 2021, 58, 2100783.	6.7	9
51	Rational use of Xpert testing in patients with presumptive TB: clinicians should be encouraged to use the test-treat threshold. BMC Infectious Diseases, 2017, 17, 674.	2.9	8
52	Better programmatic outcome with the shorter regimen for the treatment of multidrug-resistant tuberculosis (MDR-TB) in Guinea: A retrospective cohort study. PLoS ONE, 2020, 15, e0237355.	2.5	8
53	High-Dose First-Line Treatment Regimen for Recurrent Rifampicin-Susceptible Tuberculosis. American Journal of Respiratory and Critical Care Medicine, 2020, 201, 1578-1579.	5.6	8
54	Course of Adverse Events during Short Treatment Regimen in Patients with Rifampicin-Resistant Tuberculosis in Burundi. Journal of Clinical Medicine, 2020, 9, 1873.	2.4	8

#	ARTICLE	IF	CITATIONS
55	Comparison of first-line tuberculosis treatment outcomes between previously treated and new patients: a retrospective study in Machakos subcounty, Kenya. <i>International Health</i> , 2021, 13, 272-280.	2.0	8
56	Effect of reliance on Xpert MTB/RIF on time to treatment and multidrug-resistant tuberculosis treatment outcomes in Tanzania: a retrospective cohort study. <i>International Health</i> , 2019, 11, 520-527.	2.0	7
57	Translating drug resistant tuberculosis treatment guidelines to reality in war-torn Kandahar, Afghanistan: A retrospective cohort study. <i>PLoS ONE</i> , 2020, 15, e0237787.	2.5	7
58	Tuberculosis treatment: one-shot approach or cascade of regimens?. <i>Lancet Respiratory Medicine</i> , the, 2020, 8, e4-e5.	10.7	7
59	Community-Based ART Service Delivery for Key Populations in Sub-Saharan Africa: Scoping Review of Outcomes Along the Continuum of HIV Care. <i>AIDS and Behavior</i> , 2022, 26, 2314-2337.	2.7	7
60	Psychiatric comorbidities among patients with complex drug-resistant tuberculosis in Mumbai, India. <i>PLoS ONE</i> , 2022, 17, e0263759.	2.5	7
61	Operational Research during the Ebola Emergency. <i>Emerging Infectious Diseases</i> , 2017, 23, 1057-1062.	4.3	6
62	Blended SORT-IT for operational research capacity building: the model, its successes and challenges. <i>Global Health Action</i> , 2018, 11, 1469215.	1.9	6
63	Performance of algorithms for tuberculosis active case finding in underserved high-prevalence settings in Cambodia: a cross-sectional study. <i>Global Health Action</i> , 2019, 12, 1646024.	1.9	6
64	“I don’t take my pills every day, but then it goes up, goes down. I don’t know what’s going on” Perceptions of HIV virological failure in a rural context in Mozambique. A qualitative research study. <i>PLoS ONE</i> , 2019, 14, e0218364.	2.5	6
65	Temporary disengagement and re-engagement in human immunodeficiency virus care in a rural county serving pastoralist communities in Kenya: a retrospective cohort study. <i>International Health</i> , 2020, 12, 95-100.	2.0	6
66	Injectables™ key role in rifampicin-resistant tuberculosis shorter treatment regimen outcomes. <i>PLoS ONE</i> , 2020, 15, e0238016.	2.5	6
67	Knowledge transmission, peer support, behaviour change and satisfaction in post Natal clubs in Khayelitsha, South Africa: a qualitative study. <i>Reproductive Health</i> , 2020, 17, 107.	3.1	6
68	Multidrug-resistant patients receiving treatment in Niger who are infected with <i>M. tuberculosis</i> Cameroon family convert faster in smear and culture than those with <i>M. tuberculosis</i> Ghana family. <i>Tuberculosis</i> , 2020, 122, 101922.	1.9	6
69	Case Report: Dynamics of Acquired Fluoroquinolone Resistance under Standardized Short-Course Treatment of Multidrug-Resistant Tuberculosis. <i>American Journal of Tropical Medicine and Hygiene</i> , 2020, 103, 1443-1446.	1.4	6
70	Trends in tuberculosis notification and treatment outcomes in prisons: a country-wide assessment in El Salvador from 2009-2014. <i>Revista Panamericana De Salud Publica/Pan American Journal of Public Health</i> , 2016, 39, 38-43.	1.1	6
71	Mortality among PCR negative admitted Ebola suspects during the 2014/15 outbreak in Conakry, Guinea: A retrospective cohort study. <i>PLoS ONE</i> , 2017, 12, e0180070.	2.5	5
72	Virological outcomes and risk factors for non-suppression for routine and repeat viral load testing after enhanced adherence counselling during viral load testing scale-up in Zimbabwe: analytic cross-sectional study using laboratory data from 2014 to 2018. <i>AIDS Research and Therapy</i> , 2022, 19, .	1.7	5

#	ARTICLE	IF	CITATIONS
73	Utilization of and Barriers to HIV and MCH Services among Community ART Group Members and Their Families in Tete, Mozambique. <i>AIDS Research and Treatment</i> , 2013, 2013, 1-8.	0.7	4
74	Lifelong ART for 20 million people in sub-Saharan Africa: communities will be key for success. <i>The Lancet Global Health</i> , 2014, 2, e262-e263.	6.3	4
75	Twenty years of rifampicin resistance surveillance in Bangladesh: periodic vs. continuous monitoring. <i>International Journal of Tuberculosis and Lung Disease</i> , 2018, 22, 1450-1461.	1.2	4
76	Community health worker-led ART delivery improved scheduled antiretroviral drug refill among men who have sex with men in Lagos State, Nigeria. <i>International Health</i> , 2021, 13, 196-198.	2.0	4
77	Operational research: did health systems in Sierra Leone recover after the 2014-15 Ebola outbreak?. <i>F1000Research</i> , 2019, 8, 792.	1.6	4
78	Burden and outcome of HIV infection and other morbidities in health care workers attending an Occupational Health Program at the Provincial Hospital of Tete, Mozambique. <i>Tropical Medicine and International Health</i> , 2011, 16, 1450-1456.	2.3	3
79	District-level strategies to control the HIV epidemic in Zimbabwe: a practical example of precision public health. <i>BMC Research Notes</i> , 2020, 13, 393.	1.4	3
80	Fluorescein diacetate and rapid molecular testing for the early identification of rifampicin resistance in Mali. <i>International Journal of Tuberculosis and Lung Disease</i> , 2020, 24, 763-769.	1.2	3
81	Long-term retention and predictors of attrition for key populations receiving antiretroviral treatment through community-based ART in Benue State Nigeria: A retrospective cohort study. <i>PLoS ONE</i> , 2021, 16, e0260557.	2.5	3
82	Comment on: Effects of isoniazid resistance on TB treatment outcomes under programmatic conditions in a high-TB and -HIV setting: a prospective multicentre study. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 1733-1734.	3.0	2
83	Low Cycle Threshold Value in Xpert MTB/RIF Assay May Herald False Detection of Tuberculosis and Rifampicin Resistance: A Study of Two Cases. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab034.	0.9	2
84	Case Report: Therapeutic Threshold for Rifampicin-Resistant Tuberculosis in a Patient from Maputo, Mozambique. <i>American Journal of Tropical Medicine and Hygiene</i> , 2021, 104, 1317-1320.	1.4	2
85	Bedaquiline can act as core drug in a standardized treatment regimen for fluoroquinolone-resistant rifampicin-resistant tuberculosis. <i>European Respiratory Journal</i> , 2021, , 2102124.	6.7	2
86	How Second-Line Injectable Drugs Work. <i>Clinical Infectious Diseases</i> , 2021, 72, e1167-e1168.	5.8	2
87	Person-centred care and short oral treatment for rifampicin-resistant tuberculosis improve retention in care in Kandahar, Afghanistan. <i>Tropical Medicine and International Health</i> , 2022, 27, 207-215.	2.3	2
88	Multidrug-resistant tuberculosis control in Rwanda overcomes a successful clone that causes most disease over a quarter century. <i>Journal of Clinical Tuberculosis and Other Mycobacterial Diseases</i> , 2022, 27, 100299.	1.3	2
89	High mortality in non-Ebola virus disease cases: need to provide timely and effective care. <i>Lancet Infectious Diseases</i> , The, 2017, 17, 1021-1022.	9.1	1
90	Definitive outcomes in patients with rifampicin-resistant tuberculosis treated in Niger from 2012 to 2019: A retrospective cohort study. <i>International Health</i> , 2023, 15, 258-264.	2.0	1

#	ARTICLE	IF	CITATIONS
91	Continuous surveillance of drug-resistant TB burden in Rwanda: a retrospective cross-sectional study. International Health, 0, , .	2.0	1
92	Management of falsepositive rifampicin resistant Xpert MTB/RIF â€“ Authors' reply. Lancet Microbe, The, 2020, 1, e239.	7.3	0
93	Human rights: finding the right balance for rifampicin-resistant TB treatment. International Journal of Tuberculosis and Lung Disease, 2021, 25, 327-328.	1.2	0
94	Should treatment of low-level rifampicin mono-resistant tuberculosis be different?. Journal of Clinical Tuberculosis and Other Mycobacterial Diseases, 2021, 23, 100240.	1.3	0
95	Predictors of Rifampicin-Resistant Tuberculosis Mortality among HIV-Coinfected Patients in Rwanda. American Journal of Tropical Medicine and Hygiene, 2021, 105, 47-53.	1.4	0
96	â€œI donâ€™t know when he will be backâ€ life-changing events challenge the community ART Group modelâ€ a qualitative research study, Tete, Mozambique. BMC Public Health, 2021, 21, 2004.	2.9	0
97	Implications of bedaquiline-resistant tuberculosis. Lancet Infectious Diseases, The, 2022, 22, 166-167.	9.1	0
98	Tuberculosis among indigenous municipalities in Mexico: analysis of case notification and treatment outcomes between 2009 and 2013. Revista Panamericana De Salud Publica/Pan American Journal of Public Health, 2016, 39, 32-37.	1.1	0
99	Acquired rifampicin resistance during first TB treatment: magnitude, relative importance, risk factors and keys to control in low-income settings. JAC-Antimicrobial Resistance, 2022, 4, dlac037.	2.1	0
100	Title is missing!. , 2020, 15, e0222309.		0
101	Title is missing!. , 2020, 15, e0222309.		0
102	Title is missing!. , 2020, 15, e0222309.		0
103	Title is missing!. , 2020, 15, e0222309.		0
104	Injectablesâ€™ key role in rifampicin-resistant tuberculosis shorter treatment regimen outcomes. , 2020, 15, e0238016.		0
105	Injectablesâ€™ key role in rifampicin-resistant tuberculosis shorter treatment regimen outcomes. , 2020, 15, e0238016.		0
106	Injectablesâ€™ key role in rifampicin-resistant tuberculosis shorter treatment regimen outcomes. , 2020, 15, e0238016.		0
107	Injectablesâ€™ key role in rifampicin-resistant tuberculosis shorter treatment regimen outcomes. , 2020, 15, e0238016.		0
108	Title is missing!. , 2020, 15, e0233500.		0

#	ARTICLE	IF	CITATIONS
109	Title is missing!., 2020, 15, e0233500.		0
110	Title is missing!., 2020, 15, e0233500.		0
111	Title is missing!., 2020, 15, e0233500.		0